A clinical phase II trial was conducted to examine anti-IGF1R antibody CP-751,871 in combination with standard first-line chemotherapy comprising carboplatin and paclitaxel in advanced NSCLC [21], [33]. The gene discussed is IGF1R; the disease is non-small cell lung carcinoma.